David Scadden

Research addresses hurdles to future transplant-based, gene-editing therapies that could help people with genetic blood diseases HSCI scientists at Harvard's Department of Stem Cell and Regenerative Biology and the Massachusetts General Hospital Center...

A possible new approach to treating HIV/AIDS Harvard Stem Cell Institute (HSCI) researchers at Massachusetts General (MGH) and Boston Children’s hospitals for the first time have used a relatively new gene-editing technique to create what could prove to...

Harvard/MIT team finds that killing cancer cells by disrupting their metabolism doesn’t harm normal cells A study comparing how blood stem cells and leukemia cells consume nutrients found that cancer cells are far less tolerant to shifts in their energy...

Harvard stem cell scientists have a new tool to see how nimble cells are in response to changes in their environment. Rather than looking at the proteins that cells actively make, the researchers surveyed the proteins that cells choose to destroy. This...

Harvard Stem Cell Institute (HSCI) researchers have for the first time identified in mice a cellular mechanism that directs stem cells to their ultimate destination in the body. The finding in blood stem cells by HSCI co-director David Scadden and...

The general theory of cancer development holds that malignancies occur because of the presence of certain genetic elements within the affected cells. But a new study by Harvard researchers at Massachusetts General Hospital (MGH) indicates that “good”...

"The American Society of Hematology (ASH), the world’s largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding and treatment of hematologic diseases. These awards will be...

HSCI Co-Director David Scadden, MD, and Affiliated Faculty member Xi He, PhD, have each won two-year, half-million dollar competitive grants – and industry sponsorship, from the Massachusetts Life Sciences Center (MLSC), which oversees the state’s $1...

Harvard Stem Cell Institute researchers at Massachusetts General Hospital (MGH) succeeded in using reprogrammed human stem cells to make working blood vessels in mice that can survive for as long as nine months. The blood vessels were created with induced...

A bone drug already on the market for osteoporosis may kill chronic myelogenous leukemia (CML) stem cells thought to persist in the bone marrow after standard therapy, lowering the likelihood of disease recurrence, according to a new study in mice led by...